Throid Dysfunction in Liver Failure and Its Eddects Upon Outcome

NCT ID: NCT06179368

Last Updated: 2024-01-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

100 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-01-01

Study Completion Date

2024-05-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to triiodothyronine (T3) by Type 1 deiodinase.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

In clinical terms, cirrhosis is described as are either "compensated" or "decompensated." Decompensation means cirrhosis complicated by one or more of the following features: jaundice, ascites, hepatic encephalopathy (HE), or bleeding varices. Ascites is the usual first sign. Hepatorenal syndrome, hyponatremia, and spontaneous bacterial peritonitis are also features of decompensation, but in these patients, ascites invariably occurs first. Compensated cirrhotic patients have none of these features.

The liver plays an important role in the metabolism of thyroid hormones, as it is the most important organ in the peripheral conversion of tetraiodothyronine (T4) to T3 by Type 1 deiodinase.

T4 and T3 regulate the basal metabolic rate of all cells, including hepatocytes, and thereby modulate hepatic function. The liver metabolizes the THS and regulates their systemic endocrine effects. Thyroid diseases may perturb liver function; liver disease modulates thyroid hormone metabolism; and a variety of systemic diseases affect both the organs.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatic Encephalopathy Hepatic Impairment Hypothyroidism Hepatic Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Hypothroid group

throid fuction will be evaluated on admission of hepatic failure patients, and the hypothroid patients will be enroled in this group.

hypothroidism

Intervention Type DIAGNOSTIC_TEST

throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.

Euthroid group

throid fuction will be evaluated on admission of hepatic failure patients, and the euothroid patients will be enroled in this group.

euothyroid

Intervention Type DIAGNOSTIC_TEST

throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

hypothroidism

throid fuction will be evaluated on admission of hepatic failure patients, and the hypothyroid patients will be enroled in this group.

Intervention Type DIAGNOSTIC_TEST

euothyroid

throid fuction will be evaluated on admission of hepatic failure patients, and the euothyroid patients will be enroled in this group.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\- hepatic fauiure patients

Exclusion Criteria

* hypethyroid patients
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Assiut University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Emad Zarief , MD

professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Emad Zarief Kamel Said

Asyut, , Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Emad Z Kamel, M.D.

Role: primary

+201007046058

References

Explore related publications, articles, or registry entries linked to this study.

Punekar P, Sharma AK, Jain A. A Study of Thyroid Dysfunction in Cirrhosis of Liver and Correlation with Severity of Liver Disease. Indian J Endocrinol Metab. 2018 Sep-Oct;22(5):645-650. doi: 10.4103/ijem.IJEM_25_18.

Reference Type BACKGROUND
PMID: 30294575 (View on PubMed)

McCormick PA. Sherlock's Diseases of the Liver and Biliary System Textbook. Hepatic Cirrhosis. In: Dooley JS, Lok AS, Burroughs AK, Heathcote EJ, editors. 12th ed. Ch. 7. UK: Wiley-Blackwell, A John Wiley and Sons, Ltd; 2011. pp. 103-8.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

IRB121223

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.